A key plank in the FDA’s platform to slow down the development of antibiotic resistance and extend the life of medications important to humans is in place. The agency announced Wednesday it has completed the implementation of Guidance for Industry #213.
Known in the animal pharmaceutical industry as GFI
Continue Reading Drug companies delete ‘growth’ uses from animal drug labels